This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
A randomized controlled trial of estrogen treatment in men with mild cognitive impairment
This randomized, placebo-controlled, cross-over study investigated whether estrogen treatment would have a beneficial effect on tests of verbal memory in men with mild cognitive impairment (MCI). Forty-three men newly diagnosed with MCI were administered a battery of neuropsychological tests before randomly receiving 12 weeks of treatment with estrogen or placebo followed by a 12 week […]
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Shaw, Leslie M.,
Vanderstichele, Hugo,
Knapik-Czajka, Malgorzata,
Figurski, Michal,
Coart, Els,
Blennow, Kaj,
Soares, Holly,
Simon, Adam J.,
Lewczuk, Piotr,
Dean, Robert A.,
Siemers, Eric,
Potter, William,
Lee, Virginia M.-Y.,
Trojanowski, John Q.
The close correlation between abnormally low pre-mortem cerebrospinal fluid (CSF) concentrations of amyloid-β1-42 (Aβ(1-42)) and plaque burden measured by amyloid imaging as well as between pathologically increased levels of CSF tau and the extent of neurodegeneration measured by MRI has led to growing interest in using these biomarkers to predict the presence of AD plaque […]
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study
Shatunov, Aleksey,
Mok, Kin,
Newhouse, Stephen,
Weale, Michael E,
Smith, Bradley,
Vance, Caroline,
Johnson, Lauren,
Veldink, Jan H,
van Es, Michael A,
van den Berg, Leonard H.,
Robberecht, Wim,
Van Damme, Philip,
Hardiman, Orla,
Farmer, Anne E,
Lewis, Cathryn M,
Butler, Amy W,
Abel, Olubunmi,
Andersen, Peter M,
Fogh, Isabella,
Silani, Vincenzo,
Chiò, Adriano,
Traynor, Bryan J,
Melki, Judith,
Meininger, Vincent,
Landers, John E,
McGuffin, Peter,
Glass, Jonathan D,
Pall, Hardev,
Leigh, P Nigel,
Hardy, John,
Brown, Robert H,
Powell, John F,
Orrell, Richard W,
Morrison, Karen E,
Shaw, Pamela J,
Shaw, Christopher E,
Al-Chalabi, Ammar
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have shown association of a locus on chromosome 9p with ALS and linkage with ALS-frontotemporal dementia. We aimed to test whether this genomic region is also […]
Cognitive function in early clinical phase huntington disease after rivastigmine treatment
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, Michael,
Almkvist, Ove,
Axelman, Karin,
Stefanova, Elka,
Wall, Anders,
Westman, Eric,
Långström, Bengt,
Lannfelt, Lars,
Graff, Caroline,
Nordberg, Agneta
Six young related pre-symptomatic carriers of a His163Tyr mutation in the presenilin 1 gene who will develop early onset familial Alzheimer’s disease (eoFAD), and a control group of 23 non-carriers underwent (18)F-fluorodeoxyglucose positron emission tomography (FDG PET). The mutation carriers were followed-up after 2 years. Multivariate analysis showed clear separation of carriers from non-carriers on […]